The market is estimated to increase from approximately USD 4.9 billion in 2025 to USD 5.3 billion in 2026 and USD 9.4 billion by 2035, representing a CAGR of about 6.6%.
Safety testing can address a broad range of potential risks, including microbial contamination, mycoplasma, endotoxins, bioburden, viral contamination, sterility and residual host-cell proteins or DNA.
For more information on the Biologics Safety Testing Market, visit:
https://www.rootsanalysis.com/....reports/biologics-sa
Curtir
Comentario
Compartilhar
